SPECTRUM PHARMACEUTICALS, INC. Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the 59th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 9-12, 2017.
For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference website at https://ash.confex.com/ash/2017/webprogram/start.html
The following key PTCL-related abstracts and oral presentations will be presented at the ASH meeting:
| Abstract # | Type | Title | Presenter |
Date/Time
| ||||||||
| 342 | Oral | The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study | Park |
Sunday, Dec 10,
8:45 AM
Bldg B, Lvl 4, B401-402 | ||||||||
| 818 | Oral | Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study | Shustov |
Monday, Dec 11,
4:45 PM
Bldg A, Lvl 4, Marcus Aud. | ||||||||
| 1455 | Poster | North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers | Shah |
Saturday, Dec 9,
5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 | ||||||||
| 2743 | Poster | Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl | Scotto |
Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 | ||||||||
| 380 | Poster | Direct to Drug Screening as a Route to Individualized Therapy in Multiple Myeloma | Meurice |
Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 | ||||||||
| 4012 | Poster | Histone Deacetylase Inhibitors Abolish HBZ Protein Expression and Induce Cell Death in HTLV-1 Related Adult T-Cell Leukemia-Lymphoma | Ramos |
Monday, Dec 11,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 | ||||||||
| 4020 | Poster | Selective Inhibition of HDAC1 and HDAC3 Inhibits Survival of Diffuse Large Cell Lymphoma Via Epigenetic Modulation of Death Associated Protein (DAPK) | Gupta |
Monday, Dec 11
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 |
The following key EVOMELA® (melphalan) for injection-related abstracts will be presented at the ASH meeting:
| Abstract # | Type | Title | Presenter |
Date/Time Bldg A, Lvl 1, Hall A2
| ||||||||
| 2023 | Poster | Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) | Shah |
Saturday, Dec 9,
5:30 PM-7:30 PM | ||||||||
| 3296 | Poster | Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis | Shah |
Sunday, Dec 10,
6:00 PM-8:00 PM |
The following key MARQIBO® (vinCRIStine sulfate LIPOSOME injection)-related abstracts will be presented at the ASH meeting:
| Abstract # | Type | Title | Presenter |
Date/Time Bldg A, Lvl 1, Hall A2 | ||||||||
| 1549 | Poster | Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL>60 Trial of the Dshnhl | Pfreundschuh |
Saturday, Dec 9,
5:30 PM-7:30 PM | ||||||||
| 1328 | Poster | Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices | LeBlanc |
Saturday, Dec 9,
5:30 PM-7:30 PM | ||||||||
| 2554 | Poster | Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Sasaki |
Sunday, Dec 10,
6:00 PM-8:00 PM |
The following key ZEVALIN® (ibritumomab tiuxetan)-related abstracts will be presented at the ASH meeting:
| Abstract # |
| Type | Title | Presenter |
Date/Time Bldg A, Lvl 1, Hall A2 | |||||||
| 1553 | Poster | A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) | Persky |
Saturday, Dec 9,
5:30 PM-7:30 PM | ||||||||
| 4559 | Poster | Long-Term Follow up of 90y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma | Puronen |
Monday, Dec 11,
6:00 PM-8:00 PM | ||||||||
| 4066 | Poster | Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience | Agrawal |
Monday, Dec 11,
6:00 PM-8:00 PM |
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology Company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, ZEVALIN®, MARQIBO®, BELEODAQ®, EVOMELA® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005127/en/
